Agencies agree to purchase investigational antiviral if authorized by FDA
The departments of Health and Human Services and Defense will purchase 1.7 million treatment courses of an investigational antiviral drug for $1.2 billion if the Food and Drug Administration approves or authorizes the therapy, the Biden administration announced today.
If authorized, the federal government will allocate the drug (molnupiravir) to states and territories. Health care providers would order the drug directly from the distributor within those allocations, HHS said.
Related News Articles
Perspective
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The AHA provided a statement June 30 to the House Ways and Means Committee in advance of a markup July 1 where the committee will consider legislation that…
Headline
The House Appropriations Committee June 9 approved their version of the FY 2027 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
Rep. Randy Feenstra, R-Iowa, yesterday introduced a House version of the Rural Community Hospital Demonstration Program Reauthorization Act, a bill that would…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services has opened registration for its seventh annual CMS & Health Level Seven International Fast Healthcare…